Cardiovascular Drugs and Therapy

, Volume 15, Issue 1, pp 79–87 | Cite as

The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction

  • Bertram Pitt
  • Gordon Williams
  • Willem Remme
  • Felipe Martinez
  • Jose Lopez-Sendon
  • Faiez Zannad
  • James Neaton
  • Barbara Roniker
  • Steve Hurley
  • Dan Burns
  • Richard Bittman
  • Jay Kleiman


Public Health Heart Failure Myocardial Infarction Acute Myocardial Infarction Systolic Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the reninangiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.Google Scholar
  2. 2.
    Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-1736.Google Scholar
  3. 3.
    Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71: 3A-11A.Google Scholar
  4. 4.
    Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-1265.Google Scholar
  5. 5.
    Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.Google Scholar
  6. 6.
    The effect of eplerenone on wound healing, ventricular remodeling, and infarct expansion following myocardial infarction. G.D. Searle&Co., Document No. BRD99D 973; 23 June 1999.Google Scholar
  7. 7.
    A dose-ranging study of eplerenone versus placebo and spironolactone in patients with symptomatic heart failure. G.D. Searle & Co., Protocol No. IE3-97-02-011, 21 May 1997.Google Scholar
  8. 8.
    Efficacy and safety evaluation of a range of doses of SC-66110 in the treatment of mild to moderate hypertension. G.D. Searle&Co., Protocol No. EE3-96-02-010; Report No. EE3-99-06-010, 08 January 1999.Google Scholar
  9. 9.
    Investigational brochure for eplerenone (SC-66110) selective aldosterone receptor antagonist (SARA), Edition 5. G.D. Searle & Co., Document No. NE3-99-21-900, 11 August 1999.Google Scholar
  10. 10.
    de Gasparo M, Joss U, Ramjoue HP. Three new epoxyspironolactone derivatives: Characterization in vivoand in vitro.J Pharmacol Exp Ther 1987; 240: 650-656.Google Scholar
  11. 11.
    Effect of rat plasma on in vitro binding affinity of SC-66110 and spironolactone for the mineralocorticoid receptor. G.D. Searle & Co., Document No. BRD97 D 861, 10 August 2000.Google Scholar
  12. 12.
    Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. JACC 2000; 35(5): 1245-1255.Google Scholar
  13. 13.
    Guyatt GH, Feeny DH, Patrick DL. Measuring healthrelated quality of life. Ann Intern Med 1993; 118: 622-629.Google Scholar
  14. 14.
    Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol 1994; 74: 1240-1244.Google Scholar
  15. 15.
    Ware J Jr., Kosinksi M, Keller SD. A 12-item shortform health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.Google Scholar
  16. 16.
    Jenkinson C, Layte R, Jenkinson D, et al. A shorter form health survey: Can the SF-12 replicate results from the SF-36 longitudinal studies? J Public Health Med 1997; 19: 179-186.Google Scholar
  17. 17.
    Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. International Quality of Life Assessment Project. J Clin Epidemiol 1998; 51: 1171-1178.Google Scholar
  18. 18.
    Kind P. The EuroQoL instrument: An index of healthrelated quality of life. In: Spilker B, Ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven; 1996: 191-201. Google Scholar
  19. 19.
    Torrence GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5: 1-30.Google Scholar
  20. 20.
    Burnham MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care 1988; 26: 775-789.Google Scholar
  21. 21.
    Derogatis LR, Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychol Med 1983; 13: 595-605.Google Scholar
  22. 22.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.Google Scholar
  23. 23.
    Køber L, Torp-Pedersen C, Carlsen JE, et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.Google Scholar
  24. 24.
    Torp-Pedersen C, Køber L, Carlsen J on behalf of the TRACEStudy Group. Angiotensin-converting enzyme inhibition after myocardial infarction: The trandolapril cardiac evaluation study. Am Heart J 1996; 132: 235-243.Google Scholar
  25. 25.
    Hall AS, Winter C, Bogle SM, Mackintosh AF, Murray GD, Ball SG on behalf of the AIRE Study Investigators. The acute infarction ramipril efficacy (AIRE) study: Rationale, design, organization, and outcome definitions. J Cardiovasc Pharmacol 1991; 18(Suppl 2): S105-S109.Google Scholar
  26. 26.
    Pitt B, Perez A. for the Randomized Aldactone Evaluation Study Investigators. Letters to the editor. N Engl J Med 2000; 342: 132-134.Google Scholar
  27. 27.
    Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-467.Google Scholar
  28. 28.
    Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clinical Trials 1995; 16: 395-407.Google Scholar
  29. 29.
    Spargias KS, Hall AS, Ball SG. Safety concerns about digoxin after acute myocardial infarction. Lancet 1999; 354: 391-392.Google Scholar
  30. 31.
    Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Royal Statistical Society, Series A 1972; 135: 185-206.Google Scholar
  31. 32.
    Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. J Am Statistical Assoc 1958; 53: 457-481.Google Scholar
  32. 33.
    Cox DR. Regression models and life-tables. J Royal Statistical Society, Series B 1972; 34: 187-220.Google Scholar
  33. 34.
    Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.Google Scholar
  34. 35.
    Smith AGE. Spironolactone in the Long-Term Management of Patients with Congestive Heart Failure. Curr Med Res Opin 1980; 7: 131-136.Google Scholar
  35. 36.
    Muller J. Spironolactone in the management of congestive heart failure: A review. Clin Ther 1986; 9: 63-76.Google Scholar
  36. 37.
    Sun Y, Ramires FJA, Wever KT. Fibrosis of Atria and Great Vessels in Response to Angiotensin II or Aldosterone Infusion. Cardiovasc Res 1997; 35: 138-147.Google Scholar
  37. 38.
    Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677.Google Scholar
  38. 39.
    Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovascular Drugs and Therapy 1995; 9: 145-149.Google Scholar
  39. 40.
    Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995; 16(Suppl N): 103-106.Google Scholar
  40. 41.
    Struthers AD. Why does spironolactone improve mortality over and above and ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999; 47: 479-482.Google Scholar
  41. 42.
    MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces the early morning rise in heart rate failure patients. Cardiovasc Res 1997; 35: 30-34.Google Scholar
  42. 43.
    Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24(5): 571-575.Google Scholar
  43. 44.
    Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.Google Scholar
  44. 45.
    Weber KT, Janicki JS, Pick R, et al. Collagen in the hypertrophied pressure-overloaded myocardium. Circulation 1987; 75(Suppl I): I-40-I-47.Google Scholar
  45. 46.
    F. Zannad Aldosterone and Heart Failure. Eur Heart J 1995; 16(Suppl N): 98-102.Google Scholar
  46. 47.
    Struthers A. Aldosterone and artery compliance in heart failure. Eur Heart J 1998; 19: 1273.Google Scholar
  47. 48.
    Struthers AD. Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure. J Cardiac Failure 1996; 2(1): 47-54.Google Scholar
  48. 49.
    Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Mineralocorticoid antagonism reduces Ang II-induced renal injury in stroke-prone hypertensive rats. Am J Hypertension 1998; 11(Suppl): 94A.Google Scholar
  49. 50.
    Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993; 71(Suppl A): 46A-54A.Google Scholar
  50. 51.
    Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA. Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosteroneinduced hypertension and cardiac fibrosis. Am J Hypertension 1998; 11 (Suppl): 94A.Google Scholar
  51. 52.
    Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during longterm angiotensin II suppression. J Endocr 1981; 91: 457-465.Google Scholar
  52. 53.
    Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: A double blind controlled trial. Br Heart J 1984; 52: 530-535.Google Scholar
  53. 54.
    Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.Google Scholar
  54. 55.
    Hall AS, Murray GD, Ball SG on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349(9064): 1493-1497.Google Scholar
  55. 56.
    Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-55.Google Scholar
  56. 57.
    Cleland JGF, Erhardt L, Murray F, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators. Eur Heart J 1997; 18: 41-51.Google Scholar
  57. 58.
    Rodriguez JA, Godoy I, Castro P, Quintana JC, Chavez E, Corbalan R. A double-blind randomized placebo controlled study of ramipril vs. spironolactone on left ventricular remodeling after acute myocardial infarction. JACC 1997; abstract 947-9: 133A.Google Scholar
  58. 59.
    Epstein M, Menard J, Alexander JC, Roniker B. Eplerenone, a novel and selective aldosterone receptor antagonist: Effi-cacy in patients with mild to moderate hypertension. Circulation 1998; 98 (Suppl): I-98-99, Abstract 498.Google Scholar
  59. 60.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.Google Scholar
  60. 61.
    The EPISTENT Investigators. Randomized placebocontrolled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.62Google Scholar
  61. 62.
    The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 1996; 78: 902-912.Google Scholar
  62. 63.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.Google Scholar
  63. 64.
    Beta-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247: 1707-1714.Google Scholar
  64. 65.
    ISIS I (First International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous atenolol among 16,027 cases of suspected myocardial infarction: ISIS-1. Lancet 1986; 2: 57-65.Google Scholar
  65. 66.
    Kjekshus J, Pedersen R, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C.Google Scholar
  66. 67.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Am J Cardiol 1991; 68: 1436-1446Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Bertram Pitt
  • Gordon Williams
  • Willem Remme
  • Felipe Martinez
  • Jose Lopez-Sendon
  • Faiez Zannad
  • James Neaton
  • Barbara Roniker
  • Steve Hurley
  • Dan Burns
  • Richard Bittman
  • Jay Kleiman

There are no affiliations available

Personalised recommendations